20 Penn students and recent graduates awarded Fulbright grants Penn Fulbright grant recipients for 2021-22 include 12 graduating seniors, six graduate students and two recent graduates. Pictured left to right (top row) Daisy Angeles, Robyn Barrow, Saxon Bryant, Youvin Chung, Gabriel DeSantis, Megan Everts; (middle row) Samuel Goldstein, Maria Kovalchuk, Andreas Nolan, Caleb Oh, Neelima Paleti, Bhavana Penmetsa; (bottom row) John Sigmier, Claire Sliney, Marion Standefer, Edward Stevens IV, Judith Weston, Andrew Zheng. Not pictured: Rhina Allende and a student who asked to remain anonymous.
Twenty University of Pennsylvania students and alumni have been awarded Fulbright grants for the 2021-22 academic year, including 12 graduating seniors, six graduate students, and two recent graduates. They will conduct research, pursue graduate degrees, or teach English in Finland, France, Germany, Iceland, India, Mexico, Portugal, South Africa, Sout
May 12, 2021
Over nearly two decades, a new study has found, government agencies have given at least £175 million ($248 million) to develop ChAdOx, a vaccine delivery system developed by scientists at Oxford University. Charities like the Wellcome Trust have given at least a further £53 million. As much as 99% of the total disclosed funding for ChAdOx research came from public or philanthropic money. And yet ChAdOx now sits at the heart of AstraZeneca’s Covid-19 vaccine, and the company is free to profit from it at will.
To be sure, AstraZeneca has said it will sell these vaccines at no profit to the developing world “in perpetuity,” and at no profit in the West until it decides the pandemic is over. But that could be as soon as July after which AstraZeneca can cash in heavily on these years of publicly funded research, just as its competitors, such as Pfizer and Moderna, are already doing.